Our Science
OUR SCIENCE
Publications
This section includes publications related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets.* View our congress presentations here.
March 27, 2026
ACS Medicinal Chemistry Letters
DNA-Encoded Library (DEL) Selection Identifies a Distinct DDB1 Ligand Binding Site
August 18, 2025
British Journal of Clinical Pharmacology
Effect of Vepdegestrant, a PROTAC Oestrogen Receptor Degrader, on Dabigatran and Rosuvastatin Pharmacokinetics in Healthy Participants
May 31, 2025
New England Journal of Medicine
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
May 6, 2025
Targeted Oncology
PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
December 13, 2024
Molecular Cancer Therapeutics
Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
November 20, 2024
International Journal of Clinical Oncology
Safety and Pharmacokinetics of Vepdegestrant in Japanese Patients with ER+ Advanced Breast Cancer: A Phase 1 Study
November 5, 2024
Organic Process Research & Development
Development of a Commercial Manufacturing Process for Vepdegestrant, an Orally Bioavailable PROTAC Estrogen Receptor Degrader for the Treatment of Breast Cancer
September 19, 2024
Cell Chemical Biology
New Therapies on the Horizon: Targeted Protein Degradation in Neuroscience
* Vepdegestrant (VEPPANU™) is licensed to Rigel Pharmaceuticals, which holds the exclusive global development, manufacturing, and commercialization rights.